Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors.
Alexej BallhausenJennifer J WhelerDaniel D KarpSarina A Piha-PaulSiqing FuShubham PantApostolia M TsimberidouDavid S HongVivek SubbiahVeronica R HolleyHelen J HuangAbenaa M BrewsterKimberly B KoenigNuhad K IbrahimFunda Meric-BernstamFilip JankuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Everolimus, letrozole, and trastuzumab have a favorable safety profile and elicit encouraging signals of anticancer activity in patients with heavily pretreated hormone receptor- and HER2-positive advanced cancers.